Murray McKinnon, Ph.D.

Murray McKinnon, Ph.D. has extensive work experience in the pharmaceutical industry. Murray currently serves as the Chief Scientific Officer at Empress Therapeutics since January 2023. Prior to this, they held various positions at The Janssen Pharmaceutical Companies of Johnson & Johnson, including Global Head of the World Without Disease Accelerator from May 2021 to January 2023, Head of Janssen Immunosciences from January 2016 to January 2023, and Vice President and Head of Immunology Discovery from November 2008 to April 2017. Before joining Johnson & Johnson, they were the Head of Immunology Discovery at Bristol-Myers Squibb from June 2000 to November 2008. Murray'scareer began at Glaxo Wellcome in 1985 as a Group Leader, where they worked until 2000.

Murray McKinnon, Ph.D. began their education by earning a Bachelor of Science degree in Biochemistry from the University of Glasgow, a four-year program that they completed from 1981 to 1985. Subsequently, they pursued further studies at the Imperial Cancer Research Fund in London, UK (now Cancer Research UK), where they obtained their Doctor of Philosophy (Ph.D.) degree in Biochemistry. This program lasted from 1989 to 1992.